CGH
SCMP

Crossmark Global Holdings’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Crossmark Global Holdings’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-12,950
Closed -$153K – 1693
2017
Q3 		$153K Buy
+12,950
New +$145K ﹤0.01% 1592
2016
Q3 		$153K Buy
+12,950
New +$153K ﹤0.01% 1592

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Crossmark Global Holdings's SCMP Position: Q4 2017 in Review

Crossmark Global Holdings sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 12,950 shares — an estimated $153K sold.

Crossmark Global Holdings first reported a position in SCMP in Q3 2016 and held it in 2 quarters. The position peaked at $153K in Q3 2017. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

  • Crossmark Global Holdings reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Crossmark Global Holdings sold 12,950 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $153K.
  • Crossmark Global Holdings first reported a position in Sucampo Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Crossmark Global Holdings's Sucampo Pharmaceuticals, Inc. position peaked at $153K in Q3 2017.
  • 188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Crossmark Global Holdings's 13F filing for Q4 2017, filed 5 Feb 2018.